Vertex Pharmaceuticals (VRTX) Gross Margin (2009 - 2026)

Vertex Pharmaceuticals' Gross Margin history runs 18 years deep, the most recent figure standing at 86.85% for Q1 2026.

• On a quarterly basis, Gross Margin fell 5.0% year-over-year to 86.85% in Q1 2026; TTM through Mar 2026 was 86.24%, a 21.0% increase from a year earlier, with the FY2025 full-year figure at 86.24%, up 13.0% from the prior year.
• Gross Margin advanced to 86.85% in Q1 2026 per VRTX's latest filing, from 85.39% in the prior quarter.
• Across five years, Gross Margin topped out at 88.76% in Q1 2023 and bottomed at 85.38% in Q4 2023.
• The 5-year median for Gross Margin is 86.9% (2025), against an average of 86.88%.
• Across the five-year window, Gross Margin soared 79 bps in 2022 and tumbled 231 bps in 2023, its largest moves.
• Year by year, Gross Margin stood at 87.7% in 2022, then retreated by 3 bps to 85.38% in 2023, then increased by 0 bps to 85.46% in 2024, then declined by 0 bps to 85.39% in 2025, then rose by 2 bps to 86.85% in 2026.
• Per Business Quant, the three latest VRTX Gross Margin figures stand at 86.85% (Q1 2026), 85.39% (Q4 2025), and 86.52% (Q3 2025).